|
US5814651A
(en)
|
1992-12-02 |
1998-09-29 |
Pfizer Inc. |
Catechol diethers as selective PDEIV inhibitors
|
|
ATE239797T1
(de)
|
1993-01-25 |
2003-05-15 |
Takeda Chemical Industries Ltd |
Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
|
|
JPH08295667A
(ja)
*
|
1995-04-27 |
1996-11-12 |
Takeda Chem Ind Ltd |
複素環化合物、その製造法および剤
|
|
JPH08295687A
(ja)
*
|
1995-04-28 |
1996-11-12 |
Ube Ind Ltd |
無水シトラコン酸の製造法
|
|
DE19709877A1
(de)
|
1997-03-11 |
1998-09-17 |
Bayer Ag |
1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
|
|
JP3816111B2
(ja)
|
1997-04-09 |
2006-08-30 |
インテレクト・ニューロサイエンシズ・インコーポレーテッド |
β−アミロイド末端に特異的な組換え抗体、それをコードするＤＮＡ及びその使用法
|
|
US8173127B2
(en)
|
1997-04-09 |
2012-05-08 |
Intellect Neurosciences, Inc. |
Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
|
|
GB9722520D0
(en)
|
1997-10-24 |
1997-12-24 |
Pfizer Ltd |
Compounds
|
|
US6905686B1
(en)
|
1997-12-02 |
2005-06-14 |
Neuralab Limited |
Active immunization for treatment of alzheimer's disease
|
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
CZ27399A3
(cs)
|
1999-01-26 |
2000-08-16 |
Ústav Experimentální Botaniky Av Čr |
Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
|
|
CA2390948A1
(en)
*
|
1999-06-03 |
2000-12-14 |
Abbott Laboratories |
Cell adhesion-inhibiting antiinflammatory compounds
|
|
TR200103804T2
(tr)
|
1999-06-28 |
2002-05-21 |
Janssen Pharmaceutica N.V. |
Solunum sistemi sinsitiyal virüsünün replikasyonunu inhibe edici maddeler
|
|
ATE322494T1
(de)
|
2000-01-07 |
2006-04-15 |
Universitaire Instelling Antwe |
Purin derivate, ihre herstellung und verwendung
|
|
SI1481992T1
(sl)
|
2000-02-24 |
2017-01-31 |
Washington University St. Louis |
Humanizirana protitelesa, ki vežejo amiloidni peptid beta
|
|
CA2407573C
(en)
|
2000-04-27 |
2011-09-13 |
Yamanouchi Pharmaceutical Co. Ltd. |
Imidazopyridine derivatives
|
|
DE10045112A1
(de)
|
2000-09-11 |
2002-03-21 |
Merck Patent Gmbh |
Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
|
|
JP4708675B2
(ja)
|
2000-11-03 |
2011-06-22 |
プロテオテック・インコーポレーテッド |
ウンカリア・トメントーサおよび関連植物からアミロイド阻害化合物を単離する方法ならびに単離した化合物の使用
|
|
GB0115181D0
(en)
|
2001-06-20 |
2001-08-15 |
Glaxo Group Ltd |
Novel use
|
|
WO2003000697A1
(en)
|
2001-06-22 |
2003-01-03 |
Takeda Chemical Industries, Ltd. |
Furoisoquinoline derivative, process for producing the same, and use
|
|
US6919353B2
(en)
|
2001-06-27 |
2005-07-19 |
Merck Frosst Canada & Co. |
Substituted 8-arylquinolune PDE4 inhibitors
|
|
EP1405844A4
(en)
|
2001-06-29 |
2006-09-20 |
Nikken Chemicals Co Ltd |
CYCLOALKENONDERIVAT
|
|
WO2003008396A1
(en)
|
2001-07-16 |
2003-01-30 |
Nikken Chemicals Co., Ltd. |
Optically active oxazine derivative
|
|
PL366792A1
(en)
|
2001-07-18 |
2005-02-07 |
Merck Patent Gmbh |
4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1, 2, 4) triazin-5-one derivatives having a pde-iv inhibiting and tnf-antagonistic effect for the treatment of cardiac diseases and allergies
|
|
WO2003008373A1
(de)
|
2001-07-19 |
2003-01-30 |
Merck Patent Gmbh |
Tyrosinhydrazide
|
|
FR2827599A1
(fr)
|
2001-07-20 |
2003-01-24 |
Neuro3D |
Composes derives de quinoleine et quinoxaline,preparation et utilisations
|
|
GB0118373D0
(en)
|
2001-07-27 |
2001-09-19 |
Glaxo Group Ltd |
Novel therapeutic method
|
|
TWI221838B
(en)
|
2001-08-09 |
2004-10-11 |
Tanabe Seiyaku Co |
Pyrazinoisoquinoline compound or naphthalene compound
|
|
EP1285922A1
(en)
|
2001-08-13 |
2003-02-26 |
Warner-Lambert Company |
1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
|
|
FR2828693B1
(fr)
|
2001-08-14 |
2004-06-18 |
Exonhit Therapeutics Sa |
Nouvelle cible moleculaire de la neurotoxicite
|
|
AU2002333193A1
(en)
|
2001-08-15 |
2003-03-03 |
Leo Pharma A/S |
A pharmaceutical composition for dermal application
|
|
CN1568187A
(zh)
|
2001-08-15 |
2005-01-19 |
Icos股份有限公司 |
2h－2,3－二氮杂萘－1－酮和其使用方法
|
|
WO2003016466A2
(en)
|
2001-08-17 |
2003-02-27 |
Eli Lilly And Company |
ANTI-Aβ ANTIBODIES
|
|
JO2311B1
(en)
|
2001-08-29 |
2005-09-12 |
ميرك فروست كندا ليمتد |
Alkyl inhibitors Ariel phosphodiesterase-4
|
|
GB0122031D0
(en)
|
2001-09-12 |
2001-10-31 |
Pfizer Ltd |
Use of pde4 inhibitors in a dry powder inhaler
|
|
CN100496607C
(zh)
|
2001-09-19 |
2009-06-10 |
尼科梅德有限责任公司 |
Nsaid与pde-4抑制剂的并用药物
|
|
KR20040044946A
(ko)
|
2001-09-19 |
2004-05-31 |
알타나 파마 아게 |
Ｐｄｅ 억제제와 류코트리엔 수용체 길항제의 병용
|
|
WO2003035650A1
(en)
|
2001-09-25 |
2003-05-01 |
Takeda Chemical Industries, Ltd. |
Entry inhibitor
|
|
KR100614900B1
(ko)
|
2001-10-02 |
2006-08-25 |
파마시아 앤드 업존 캄파니 엘엘씨 |
질병의 치료를 위한 아자비시클릭-치환된 융합-헤테로아릴화합물
|
|
GB0123951D0
(en)
|
2001-10-05 |
2001-11-28 |
Glaxo Group Ltd |
Therapies for treating respiratory diseases
|
|
DE10150517A1
(de)
|
2001-10-12 |
2003-04-17 |
Merck Patent Gmbh |
Verwendung von Phosphodiesterase IV-Inhibitoren
|
|
BR0213660A
(pt)
|
2001-10-16 |
2004-08-24 |
Memory Pharm Corp |
Composto, composição farmacêutica e método para tratar pacientes
|
|
AU2002343604C1
(en)
|
2001-10-30 |
2009-09-17 |
Conforma Therapeutics Corporation |
Purine analogs having HSP90-inhibiting activity
|
|
MXPA04003668A
(es)
|
2001-10-31 |
2004-07-22 |
Merck Patent Gmbh |
Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
|
|
ATE541847T1
(de)
|
2001-11-01 |
2012-02-15 |
Icagen Inc |
Pyrazolopyrimidine als natriumkanalblocker
|
|
US20030195205A1
(en)
|
2001-11-02 |
2003-10-16 |
Pfizer Inc. |
PDE9 inhibitors for treating cardiovascular disorders
|
|
AR037517A1
(es)
|
2001-11-05 |
2004-11-17 |
Novartis Ag |
Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
|
|
EP1441730B1
(en)
|
2001-11-05 |
2006-08-09 |
Merck Patent GmbH |
Hydrazono-malonitriles
|
|
US20030092706A1
(en)
|
2001-11-09 |
2003-05-15 |
Johannes Barsig |
Combination
|
|
IS7221A
(is)
|
2001-11-15 |
2004-04-15 |
Memory Pharmaceuticals Corporation |
Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og aðferðir til notkunar þeirra
|
|
FR2832711B1
(fr)
|
2001-11-26 |
2004-01-30 |
Warner Lambert Co |
Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
|
|
US20050101000A1
(en)
|
2002-12-11 |
2005-05-12 |
Isis Pharmaceuticals Inc. |
Modulation of phosphodiesterase 4B expression
|
|
DE10238724A1
(de)
|
2002-08-23 |
2004-03-04 |
Bayer Ag |
Alkyl-substituierte Pyrazolpyrimidine
|
|
DE10238723A1
(de)
|
2002-08-23 |
2004-03-11 |
Bayer Ag |
Phenyl-substituierte Pyrazolyprimidine
|
|
CA2501945A1
(en)
|
2002-10-09 |
2004-04-22 |
Rinat Neuroscience Corp. |
Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
|
|
AU2003283303A1
(en)
|
2002-11-08 |
2004-06-07 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b)
|
|
AU2003299651A1
(en)
|
2002-12-11 |
2004-06-30 |
Merck And Co., Inc. |
Tyrosine kinase inhibitors
|
|
WO2004089471A2
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
|
|
WO2004089380A2
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Pharmaceutical use of fused 1,2,4-triazoles
|
|
US20040220186A1
(en)
|
2003-04-30 |
2004-11-04 |
Pfizer Inc. |
PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
|
|
US7741341B2
(en)
|
2003-05-19 |
2010-06-22 |
Sanofi-Aventis Deutschland Gmbh |
Benzimidazole-derivatives as factor Xa inhibitors
|
|
EP1638935A1
(en)
|
2003-06-19 |
2006-03-29 |
Pfizer Products Inc. |
Nk1 antagonist
|
|
AU2004253543B2
(en)
|
2003-07-01 |
2009-02-19 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
|
FR2857966A1
(fr)
|
2003-07-24 |
2005-01-28 |
Aventis Pharma Sa |
Produits aryl-heteroaromatiques, compositions les contenant et utilisation
|
|
US20050020587A1
(en)
|
2003-07-25 |
2005-01-27 |
Pfizer Inc |
Nicotinamide derivatives useful as PDE4 inhibitors
|
|
CA2538220A1
(en)
|
2003-09-09 |
2005-03-24 |
Takeda Pharmaceutical Company Limited |
Use of antibody
|
|
GB0322726D0
(en)
|
2003-09-27 |
2003-10-29 |
Glaxo Group Ltd |
Compounds
|
|
GB0322722D0
(en)
|
2003-09-27 |
2003-10-29 |
Glaxo Group Ltd |
Compounds
|
|
EP1668024A4
(en)
|
2003-09-29 |
2008-07-02 |
Topigen Pharma Inc |
OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES INCLUDING INFLAMMATORY SUFFERING
|
|
GB0327319D0
(en)
|
2003-11-24 |
2003-12-24 |
Pfizer Ltd |
Novel pharmaceuticals
|
|
US20050137234A1
(en)
|
2003-12-19 |
2005-06-23 |
Syrrx, Inc. |
Histone deacetylase inhibitors
|
|
BRPI0507374A
(pt)
|
2004-02-02 |
2007-07-10 |
Pfizer Prod Inc |
moduladores do receptor de histamina-3
|
|
JP2008503446A
(ja)
|
2004-05-06 |
2008-02-07 |
プレキシコン，インコーポレーテッド |
Ｐｄｅ４ｂ阻害剤及びその使用
|
|
US7456164B2
(en)
|
2004-05-07 |
2008-11-25 |
Pfizer, Inc |
3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
|
|
EP1595881A1
(en)
|
2004-05-12 |
2005-11-16 |
Pfizer Limited |
Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
|
|
TWI355389B
(en)
|
2004-07-30 |
2012-01-01 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide a
|
|
CA2583428A1
(en)
|
2004-09-03 |
2006-03-09 |
Plexxikon, Inc. |
Bicyclic heteroaryl pde4b inhibitors
|
|
GB0420719D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
|
JP5080256B2
(ja)
|
2004-09-20 |
2012-11-21 |
ゼノン・ファーマシューティカルズ・インコーポレイテッド |
二環式複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼ（ＳＣＤ）のインヒビターとしてのそれらの使用
|
|
KR20070057965A
(ko)
|
2004-09-21 |
2007-06-07 |
신타 파마슈티칼스 코프. |
염증 및 면역 관련 용도를 위한 화합물
|
|
FR2877015B1
(fr)
|
2004-10-21 |
2007-10-26 |
Commissariat Energie Atomique |
Revetement nanostructure et procede de revetement.
|
|
DE102004054634A1
(de)
*
|
2004-11-12 |
2006-05-18 |
Schwarz Pharma Ag |
Azaindolcarboxamide
|
|
WO2006069081A2
(en)
|
2004-12-22 |
2006-06-29 |
Washington University In St. Louis |
USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
|
|
JPWO2006088246A1
(ja)
|
2005-02-18 |
2008-07-10 |
武田薬品工業株式会社 |
Ｇｐｒ３４受容体機能調節剤
|
|
GB0503955D0
(en)
|
2005-02-25 |
2005-04-06 |
Glaxo Group Ltd |
Novel compounds
|
|
UY29504A1
(es)
|
2005-04-29 |
2006-10-31 |
Rinat Neuroscience Corp |
Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
|
|
PL1881985T3
(pl)
|
2005-05-12 |
2011-05-31 |
Pfizer |
Bezwodne krystaliczne postacie N-[1-(2-etoksyetylo)-5-(N-etylo-N-metyloamino)-7-(4-metylopirydyn-2-yloamino)-1H-pirazolo[4,3-d]pirymidyno-3-karbonylo]metano-sulfonoamidu
|
|
CA2603830A1
(en)
|
2005-05-24 |
2006-11-30 |
Pharmacia & Upjohn Co Llc |
PYRIDINE [2,3-B] PYRAZINONES
|
|
WO2006126083A1
(en)
|
2005-05-24 |
2006-11-30 |
Pharmacia & Upjohn Company Llc |
Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
|
|
WO2006126082A2
(en)
|
2005-05-24 |
2006-11-30 |
Pharmacia & Upjohn Company Llc |
Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
|
|
WO2006136924A1
(en)
|
2005-06-22 |
2006-12-28 |
Pfizer Products Inc. |
Histamine-3 receptor antagonists
|
|
US8158673B2
(en)
|
2005-10-27 |
2012-04-17 |
Pfizer Inc. |
Histamine-3 receptor antagonists
|
|
JP2009514846A
(ja)
|
2005-11-04 |
2009-04-09 |
ファイザー・リミテッド |
テトラヒドロナフチリジン誘導体
|
|
WO2007063385A2
(en)
|
2005-12-01 |
2007-06-07 |
Pfizer Products Inc. |
Spirocyclic amine histamine-3 receptor antagonists
|
|
WO2007069053A1
(en)
|
2005-12-14 |
2007-06-21 |
Pfizer Products Inc. |
Benzimidazole antagonists of the h-3 receptor
|
|
WO2007088462A1
(en)
|
2006-02-01 |
2007-08-09 |
Pfizer Products Inc. |
Spirochromane antagonists of the h-3 receptor
|
|
WO2007088450A2
(en)
|
2006-02-01 |
2007-08-09 |
Pfizer Products Inc. |
Chromane antagonist of the h-3 receptor
|
|
WO2007099423A1
(en)
|
2006-03-02 |
2007-09-07 |
Pfizer Products Inc. |
1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
|
|
EP2007749A2
(en)
|
2006-03-13 |
2008-12-31 |
Pfizer Products Inc. |
Tetralines antagonists of the h-3 receptor
|
|
GB0605462D0
(en)
|
2006-03-17 |
2006-04-26 |
Glaxo Group Ltd |
Novel compounds
|
|
CA2649775C
(en)
|
2006-04-21 |
2011-05-31 |
Pfizer Products Inc. |
Pyridine[3,4-b]pyrazinones
|
|
WO2007138431A2
(en)
|
2006-05-30 |
2007-12-06 |
Pfizer Products Inc. |
Azabicyclic ether histamine-3 antagonists
|
|
US20080090834A1
(en)
|
2006-07-06 |
2008-04-17 |
Pfizer Inc |
Selective azole pde10a inhibitor compounds
|
|
KR20150004441A
(ko)
|
2006-07-07 |
2015-01-12 |
칼립시스, 인코포레이티드 |
Ｐｄｅ４의 바이사이클릭 헤테로아릴 억제제
|
|
US8138205B2
(en)
|
2006-07-07 |
2012-03-20 |
Kalypsys, Inc. |
Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
|
|
PT2054416E
(pt)
|
2006-08-04 |
2011-04-06 |
Merz Pharma Gmbh & Co Kgaa |
Pirazolopirimidinas substituídas, um processo para a sua preparação e a sua utilização como medicamento
|
|
EP1900739A1
(en)
|
2006-08-30 |
2008-03-19 |
Cellzome Ag |
Diazolodiazine derivatives as kinase inhibitors
|
|
WO2008033739A2
(en)
*
|
2006-09-12 |
2008-03-20 |
Neurogen Corporation |
Benzimidazole carboxamide derivatives
|
|
WO2008045664A2
(en)
|
2006-10-06 |
2008-04-17 |
Kalypsys, Inc. |
Heterocyclic pde4 inhibitors as antiinflammatory agents
|
|
WO2008045663A2
(en)
|
2006-10-06 |
2008-04-17 |
Kalypsys, Inc. |
Aryl-substituted heterocyclic pde4 inhibitors as antiinflammatory agents
|
|
US20080102475A1
(en)
|
2006-10-13 |
2008-05-01 |
Zhengyan Kan |
Alternatively spliced isoform of phosphodiesterase 4B (PDE4B)
|
|
CL2007002994A1
(es)
|
2006-10-19 |
2008-02-08 |
Wyeth Corp |
Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
|
|
WO2008056176A1
(en)
|
2006-11-10 |
2008-05-15 |
Scottish Biomedical Limited |
Pyrazolopyrimidines as phosphodiesterase inhibitors
|
|
WO2008090429A1
(en)
|
2007-01-22 |
2008-07-31 |
Pfizer Products Inc. |
Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
|
|
WO2009023623A1
(en)
|
2007-08-10 |
2009-02-19 |
H, Lundbeck A/S |
Heteroaryl amide analogues
|
|
CN101842098A
(zh)
|
2007-08-10 |
2010-09-22 |
基因实验室技术有限公司 |
用于治疗病毒感染的含氮的二环化学实体
|
|
EP2085398A1
(en)
|
2008-02-01 |
2009-08-05 |
Merz Pharma GmbH & Co. KGaA |
Pyrazolopyrimidines, a process for their preparation and their use as medicine
|
|
WO2009108551A2
(en)
|
2008-02-25 |
2009-09-03 |
H. Lundbeck A/S |
Heteroaryl amide analogues
|
|
GB2461702A
(en)
|
2008-07-08 |
2010-01-13 |
Dyson Technology Ltd |
Hand drying apparatus
|
|
US9643922B2
(en)
|
2008-08-18 |
2017-05-09 |
Yale University |
MIF modulators
|
|
WO2010034738A2
(en)
|
2008-09-24 |
2010-04-01 |
Basf Se |
Pyrazole compounds for controlling invertebrate pests
|
|
WO2010059836A1
(en)
|
2008-11-20 |
2010-05-27 |
Decode Genetics Ehf |
Substituted aza-bridged bicyclics for cardiovascular and cns disease
|
|
US20100204265A1
(en)
|
2009-02-09 |
2010-08-12 |
Genelabs Technologies, Inc. |
Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
|
|
AU2010224485B2
(en)
|
2009-03-20 |
2014-04-17 |
Hg&H Pharmaceuticals (Pty) Ltd |
Use of pharmaceutical compositions containing mesembrenone
|
|
KR101774035B1
(ko)
|
2009-10-30 |
2017-09-01 |
얀센 파마슈티카 엔.브이. |
이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도
|
|
WO2011064237A1
(en)
|
2009-11-25 |
2011-06-03 |
Merz Pharma Gmbh & Co. Kgaa |
Crystalline forms of substituted pyrazolopyrimidines
|
|
AR079451A1
(es)
|
2009-12-18 |
2012-01-25 |
Nycomed Gmbh |
Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
|
|
US8450354B2
(en)
|
2010-03-23 |
2013-05-28 |
High Point Pharmaceuticals, Llc |
Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as β-secretase inhibitors
|
|
EP2569285A1
(en)
|
2010-05-10 |
2013-03-20 |
Gilead Sciences, Inc. |
Bifunctional quinoline derivatives
|
|
WO2011143106A1
(en)
|
2010-05-10 |
2011-11-17 |
Gilead Sciences, Inc. |
Bi - functional pyrazolopyridine compounds
|
|
WO2012067822A1
(en)
|
2010-11-16 |
2012-05-24 |
Abbott Laboratories |
Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators
|
|
US9096605B2
(en)
|
2011-08-24 |
2015-08-04 |
Glaxosmithkline Llc |
Pyrazolopyrimidine derivatives as PI3 kinase inhibitors
|
|
MA38333A1
(fr)
|
2013-02-19 |
2017-02-28 |
Pfizer |
Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
|
|
US9193736B2
(en)
|
2013-06-11 |
2015-11-24 |
Janssen Pharmaceutica, Nv |
PDE 10a inhibitors for the treatment of type II diabetes
|
|
GB201321734D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic Agents
|
|
US11497586B2
(en)
|
2014-03-21 |
2022-11-15 |
Align Technology, Inc. |
Segmented orthodontic appliance with elastics
|
|
EP3172210B1
(en)
|
2014-07-24 |
2020-01-15 |
Pfizer Inc |
Pyrazolopyrimidine compounds
|
|
DK3177624T3
(da)
|
2014-08-06 |
2019-07-01 |
Pfizer |
Imidazopyridazinforbindelser
|